Angel E. Alsina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angel E. Alsina has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Adam Gordon
3 shared publicationsElizabeth Cece
3 shared publicationsErin S. Parkinson
3 shared publications- Guy W. Neff
University of Cincinnati
3 shared publications Macnish B. Christian
3 shared publications- Nyingi Kemmer
University of Cincinnati, Cincinnati, OH 45267-0595, USA
3 shared publications
Latest Publications
- Open Access
- 16 December 2019
- Published by S. Karger AG in Liver Cancer
- Vol. 9 (1) , 93-104
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
Introduction: Understanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period. Methods: The follow-up period commenced at the first off-treatment visit after stopping the study medication and continued until study termination, withdrawal of consent, or death. OS and objective response rate were calculated for patients who did or did not receive poststudy anticancer medication for both treatment arms, as well as for the overall cohort. We investigated the subset of patients who responded to first-line treatment and subsequently received anticancer medication. Results: The OS for patients initially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 0.67–1.14). The OS for patients who initially received first-line lenvatinib (versus first-line sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75–1.09). Responders to first-line lenvatinib who received subsequent medication had a median OS of 25.7 months (95% CI 18.5–34.6); responders to first line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 14.6–not evaluable). Conclusions: In this post hoc analysis of all patients in the REFLECT study who received subsequent anticancer medication, OS was increased compared with patients who did not receive any subsequent anticancer medication. In a subset analysis of responders who had received subsequent anticancer medication, use of first-line lenvatinib led to a slightly longer median OS; more research is needed on the benefits of using first-line lenvatinib compared with sorafenib.
- 16 December 2019
- Published by S. Karger AG in Liver Cancer
- Vol. 9 (1) , 93-104
Open AccessEffects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
Introduction: Understanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period. Methods: The follow-up period commenced at the first off-treatment visit after stopping the study medication and continued until study termination, withdrawal of consent, or death. OS and objective response rate were calculated for patients who did or did not receive poststudy anticancer medication for both treatment arms, as well as for the overall cohort. We investigated the subset of patients who responded to first-line treatment and subsequently received anticancer medication. Results: The OS for patients initially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 0.67–1.14). The OS for patients who initially received first-line lenvatinib (versus first-line sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75–1.09). Responders to first-line lenvatinib who received subsequent medication had a median OS of 25.7 months (95% CI 18.5–34.6); responders to first line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 14.6–not evaluable). Conclusions: In this post hoc analysis of all patients in the REFLECT study who received subsequent anticancer medication, OS was increased compared with patients who did not receive any subsequent anticancer medication. In a subset analysis of responders who had received subsequent anticancer medication, use of first-line lenvatinib led to a slightly longer median OS; more research is needed on the benefits of using first-line lenvatinib compared with sorafenib.
- 12 May 2018
- Published by Elsevier in The American Journal of Surgery
- Vol. 216 (3) , 518-523
Outcomes of abdominal surgeries in cirrhotic patients performed by liver transplant surgeons: Are these safe?
- 12 May 2018
- Published by Elsevier in The American Journal of Surgery
- Vol. 216 (3) , 518-523
Outcomes of abdominal surgeries in cirrhotic patients performed by liver transplant surgeons: Are these safe?
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1699 Hospitalization Trends of Spontaneous Bacterial Peritonitis Over the Past Decade
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1699 Hospitalization Trends of Spontaneous Bacterial Peritonitis Over the Past Decade
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1698 Hospitalizations Outcomes in Portal Hypertension Complications Treated With Rifaximin or Lactulose Therapy
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1698 Hospitalizations Outcomes in Portal Hypertension Complications Treated With Rifaximin or Lactulose Therapy
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1703 Recurrence of Spontaneous Bacterial Peritonitis in the Setting of Antibiotic Prophylaxis While Managed on Rifaximin or Lactulose
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1703 Recurrence of Spontaneous Bacterial Peritonitis in the Setting of Antibiotic Prophylaxis While Managed on Rifaximin or Lactulose